Studies of novel agents with data available for success of stem cell collection
| Reference . | Treatment regimen . | No. . | Clinical trial . | Mobilization regimen . | CD34 yield, ×106/kg . | P . | Days of leukapheresis . | Failed collection % (definition) . |
|---|---|---|---|---|---|---|---|---|
| Breitkreutz et al54 | TAD | 93 | Phase 3 (GMMG-HD3) | CAD | 9.8 (2-33.6) | .02 | 1 (1-6) | 4 (< 2.5 × 106/kg) |
| VAD | 105 | 10.9 (3-36) | 1 (1-7) | 7 | ||||
| Breitkreutz et al54 | TAD | 100 | Phase 3 (HOVON-50) | CAD | 7.4 (2-33) | .009 | 1 (1-4) | 3 (< 2.5 × 106/kg) |
| VAD | 100 | 9.4 (0-48.7) | 1 (1-4) | 5 | ||||
| Rajkumar et al15 * | TD | 99 | Phase 3 (E1A00) | Various | NA | NA | NA | 10 (NA) |
| D | 100 | NA | 10 | |||||
| Cavo et al18 | TD | 100 | Matched pair analysis | CTX + G-CSF | 7.85 | .4 | 2 | 17 (< 4 × 106/kg) |
| VAD | 100 | 10.5 | 2 | 12 | ||||
| Kumar et al33 | Dex | 78 | Retrospective | G-CSF | 9.6 (1-18) | < .01 | 3 (1–10) | 1 (< 2.5 × 106/kg) |
| VAD | 22 | 9.8 (2.1-16.2) | 4 (2–10) | 1 | ||||
| TD | 99 | 10.0 (3.5-30.1) | 4 (1–10) | 0 | ||||
| LD | 43 | 7.9 (0-15.6) | 5 (1–12) | 3 | ||||
| Mazumder et al55 | LD | 28 | Retrospective | G-CSF | 5.4 (0-17.5) | NA | NA | 43 (< 2 × 106/kg) |
| Paripati et al56 | Other | 41 | Retrospective | G-CSF | 7.4 | .003 | 7.3 (< 2 × 106/kg) | |
| LD | 20 | 5.1 | 45 | |||||
| Rajkumar et al12 † | LD | 223 | Phase 3 (E4A03) | Various | NA | NA | 3 (NA) | |
| Ld | 220 | 3 (NA) | ||||||
| Kumar et al57 | LD/Ld | 92 | Retrospective | G-CSF | 7.9 (0-16) | NA | 11 (< 2.5 × 106/kg) | |
| 11 | CTX + G-CSF | 8.6 (0-21) | ||||||
| Mark et al58 | BiRD | 9 | Retrospective | G-CSF | 3.1 (0.2-8.6) | < .01 | 3 (< 4 × 106/kg) | |
| 19 | CTX + G-CSF | 14.2 (4.9-236) | 0 | |||||
| Cook et al59 | LD | 21 | Retrospective | CTX + G-CSF (4 with G-CSF ± AMD3100) | 6.3 (2.4-19.7) | 3 (1-8) | 9 (< 2.5 × 106/kg) | |
| 137 | 7.3 (2.4-72.5) | 2 (1-11) | 1.5 | |||||
| Popat et al60 | LD | 64 | Retrospective | G-CSF | NA | 25 (< 2 × 106/kg in 4 days) | ||
| Other | 238 | 4 | ||||||
| Jagannath et al21 | BD | 8 | 13·20 (7·2-16·1 | 2 (2-3) | 0 | |||
| Harousseau et al17 | BD | 240 | Phase 3 (IFM 2005-01) | G-CSF | 6.8 | 2.0 (mean) | 4 (< 2 × 106/kg) | |
| VAD | 242 | 8.4 | 1.6 (mean) | 2 | ||||
| Sonneveld et al20 | BAD | 150 | HOVON-65 | CTX + G-CSF | 10.48 (4-37) | 1 (1-5) | ||
| VAD | 150 | 9.26 (4.1-37.6) | 1 (1-4) | |||||
| Richardson et al51 | VRD | 23 | Phase 2 | GCSF | 6.2 | 8.7 |
| Reference . | Treatment regimen . | No. . | Clinical trial . | Mobilization regimen . | CD34 yield, ×106/kg . | P . | Days of leukapheresis . | Failed collection % (definition) . |
|---|---|---|---|---|---|---|---|---|
| Breitkreutz et al54 | TAD | 93 | Phase 3 (GMMG-HD3) | CAD | 9.8 (2-33.6) | .02 | 1 (1-6) | 4 (< 2.5 × 106/kg) |
| VAD | 105 | 10.9 (3-36) | 1 (1-7) | 7 | ||||
| Breitkreutz et al54 | TAD | 100 | Phase 3 (HOVON-50) | CAD | 7.4 (2-33) | .009 | 1 (1-4) | 3 (< 2.5 × 106/kg) |
| VAD | 100 | 9.4 (0-48.7) | 1 (1-4) | 5 | ||||
| Rajkumar et al15 * | TD | 99 | Phase 3 (E1A00) | Various | NA | NA | NA | 10 (NA) |
| D | 100 | NA | 10 | |||||
| Cavo et al18 | TD | 100 | Matched pair analysis | CTX + G-CSF | 7.85 | .4 | 2 | 17 (< 4 × 106/kg) |
| VAD | 100 | 10.5 | 2 | 12 | ||||
| Kumar et al33 | Dex | 78 | Retrospective | G-CSF | 9.6 (1-18) | < .01 | 3 (1–10) | 1 (< 2.5 × 106/kg) |
| VAD | 22 | 9.8 (2.1-16.2) | 4 (2–10) | 1 | ||||
| TD | 99 | 10.0 (3.5-30.1) | 4 (1–10) | 0 | ||||
| LD | 43 | 7.9 (0-15.6) | 5 (1–12) | 3 | ||||
| Mazumder et al55 | LD | 28 | Retrospective | G-CSF | 5.4 (0-17.5) | NA | NA | 43 (< 2 × 106/kg) |
| Paripati et al56 | Other | 41 | Retrospective | G-CSF | 7.4 | .003 | 7.3 (< 2 × 106/kg) | |
| LD | 20 | 5.1 | 45 | |||||
| Rajkumar et al12 † | LD | 223 | Phase 3 (E4A03) | Various | NA | NA | 3 (NA) | |
| Ld | 220 | 3 (NA) | ||||||
| Kumar et al57 | LD/Ld | 92 | Retrospective | G-CSF | 7.9 (0-16) | NA | 11 (< 2.5 × 106/kg) | |
| 11 | CTX + G-CSF | 8.6 (0-21) | ||||||
| Mark et al58 | BiRD | 9 | Retrospective | G-CSF | 3.1 (0.2-8.6) | < .01 | 3 (< 4 × 106/kg) | |
| 19 | CTX + G-CSF | 14.2 (4.9-236) | 0 | |||||
| Cook et al59 | LD | 21 | Retrospective | CTX + G-CSF (4 with G-CSF ± AMD3100) | 6.3 (2.4-19.7) | 3 (1-8) | 9 (< 2.5 × 106/kg) | |
| 137 | 7.3 (2.4-72.5) | 2 (1-11) | 1.5 | |||||
| Popat et al60 | LD | 64 | Retrospective | G-CSF | NA | 25 (< 2 × 106/kg in 4 days) | ||
| Other | 238 | 4 | ||||||
| Jagannath et al21 | BD | 8 | 13·20 (7·2-16·1 | 2 (2-3) | 0 | |||
| Harousseau et al17 | BD | 240 | Phase 3 (IFM 2005-01) | G-CSF | 6.8 | 2.0 (mean) | 4 (< 2 × 106/kg) | |
| VAD | 242 | 8.4 | 1.6 (mean) | 2 | ||||
| Sonneveld et al20 | BAD | 150 | HOVON-65 | CTX + G-CSF | 10.48 (4-37) | 1 (1-5) | ||
| VAD | 150 | 9.26 (4.1-37.6) | 1 (1-4) | |||||
| Richardson et al51 | VRD | 23 | Phase 2 | GCSF | 6.2 | 8.7 |
TAD indicates thalidomide, doxorubicin, and dexamethasone; VAD, vincristine, doxorubicin, and dexamethasone; CAD, cyclophosphamide 1 g/m2 per day, iv, on day 1; doxorubicin 15 mg/m2 per day, iv, on days 1 to 4; dexamethasone 40 mg orally, days 1-4, and granulocyte colony-stimulating factor (G-CSF); NA, not available; TD, thalidomide, dexamethasone; CTX, cyclophosphamide; LD, lenalidomide, dexamethasone; Ld, lenalidomide and weekly dexamethasone; and BD, bortezomib and dexamethasone.
Information on whether a stem cell harvest was attempted was available only for 79% of patients, among whom 37% attempted stem cell harvest. Collection details were not available.
Details of stem cell collection regarding cell counts and definition of failure were not available and are likely to represent a mix of practices given the multicenter nature of trial.